Steffy Jose

569 A phase 1/2 study of KSQ-004EX: autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and regnase-1, in patients with select advanced solid tumors

Rodabe Navroze Amaria, Khaled S. Sanber, George R. Blumenschein, Mehmet Altan et autres

Background The effectiveness and durability of TIL therapy may be limited by the immunosuppressive tumor microenvironment and baseline functionality of transferred T-cells. Through KSQ Therapeutics’ CRISPR 2® platform, a novel method for screening optimal combinatorial targets for enhancing T-cell anti-tumor efficacy in …

us (code pays fourni par la source)

OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma.

Rodabe Navroze Amaria, Adi Diab, Hussein Abdul-Hassan Tawbi, Isabella Claudia Glitza et autres

9519 Background: Non-engineered TIL cell therapy is approved for ICI-resistant advanced melanoma, but requires co-administration of toxic high-dose IL2. OBX-115 engineered TIL express mbIL15 under pharmacologic regulation using the FDA-approved small-molecule drug acetazolamide (ACZ), abrogating the need for IL2. We present data …

us (code pays fourni par la source)

OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.

Rodabe Navroze Amaria, Jennifer Leigh McQuade, Michael A. Davies, Isabella Claudia Glitza et autres

9515 Background: Investigational unengineered TIL cell therapy has shown promising activity in ICI-resistant metastatic melanoma but requires systemic high-dose IL2, which has well-described high-grade toxicity frequently requiring specialized management and limiting pt eligibility. OBX-115 autologous engineered TIL cell therapy does not require …

us (code pays fourni par la source)

Abstract CT176: OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma

Rodabe Navroze Amaria, Jennifer Leigh McQuade, Michael A. Davies, Isabella C. Glitza Oliva et autres

Abstract Introduction: Treatment options are limited for pts with ICI-resistant metastatic melanoma. Investigational unengineered TIL cell therapy has shown promising activity in this setting, but co-administration of systemic high-dose IL2 limits pt eligibility and is associated with safety risks. OBX-115 is an …

us (code pays fourni par la source)

TARGETED BONE MARROW RADIOABLATION ENHANCES HEMATOPOIETIC CHIMERISM AND PREVENTION DIABETES ONSET IN NOD MICE.

Antonello Pileggi, Ruth Damaris Molano, Steffy Jose, Elsie Zahr et autres

Pileggi, A1; Molano, R D.1; Jose, S S.1; Zahr, E1; Molina, J1; An, W1; Gonzalez-Quintana, J1; Atkinson, M A.2; Ricordi, C1; Inverardi, L1 Author Information

us (code pays fourni par la source)

New NICE guidelines for UTI management: what will change?

Steffy Jose, E-S. Sharif

Abstract Background In coronavirus disease 2019 (COVID-19), finding sensitive biomarkers is critical for detecting severe cases early and intervening effectively. Objectives To compare and evaluate the predictive value of C-reactive protein (CRP), interleukin-6 (IL-6), and their derived immune-inflammatory indices (CRP/albumin (CRP/alb), lymphocyte/CRP …

gb (code pays fourni par la source)

Rapamycin Impairs β-Cell Proliferation In Vivo

Elsie Zahr, Ruth Damaris Molano, Antonello Pileggi, Hirohito Ichii et autres

us (code pays fourni par la source)

Prolonged Islet Allograft Survival by Alpha-1 Antitrypsin: The Role of Humoral Immunity

Ruth Damaris Molano, Antonello Pileggi, Sihong Song, Elsie Zahr et autres

us (code pays fourni par la source)